Geriatric Assessment for Older Adults Before CAR-T or Bispecific Therapy
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial studies how a simple geriatric assessment (a check-up for older adults) can help predict side effects and outcomes in patients aged 65+ who are about to receive CAR-T cell therapy or bispecific antibody treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years old or older.
- You are scheduled to receive CAR-T cell therapy or bispecific antibody treatment.
- You can understand and sign a consent form.
- You speak and understand German or French well enough for a medical conversation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called bispecific CAR T cells that target two markers (CD19 and CD20) on cancer cells. It is for people with certain B-cell blood cancers that have come back or not responded to other treatments.
This study tests whether extra geriatric support before and after CAR-T cell therapy helps people 60 and older recover faster. It is for patients with B-cell non-Hodgkin lymphoma or multiple myeloma who are scheduled for an FDA-approved CAR-T treatment.
This study looks at how well CAR-T cell therapy works and how safely it can be given to older adults. It is for people whose cancer or related blood condition has come back or did not respond, and who are receiving a standard (commercial) CAR-T product.
This trial studies the immune system of adults 65 and older with multiple myeloma that has come back or not responded to treatment. It looks at how their immune fitness may affect their ability to receive newer therapies like CAR-T cells or bispecific antibodies.
This study looks at how your immune system responds after you receive CAR-T cell therapy for multiple myeloma. The goal is to learn more about the treatment's effects and how well it works.
This study looks at how CAR-T therapy affects blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas/leukemias. You will provide biological samples to help researchers understand these effects.
Hear when a new CART Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.